Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Loans
    Loans
    HomeNewsBaxter

    Baxter

    Jump to

    • Syngene: Multi-year contract with Zoetis adds to long-term visibility

      The risk to watch is the execution in the field biologics and the pending regulatory approvals

    • Syngene: Heavy investment phase makes it a long-term play

      Beyond contract research, another trend to watch for Syngene is the pick-up in contract manufacturing business in biologics and APIs

    • After Baxter deal, Claris may opt for delisting: Nirmal Bang

      Manchanda said he would like to hear from the management with regard to the distribution of the proceeds of the deal. If Claris' management decides to delist the company, it may opt for a share buyback as dividend payout involves distribution tax, he added.

    • Eurolife to buy Baxter India's form-fill-seal infusion business

      Specialty pharmaceuticals firm Eurolife Healthcare has entered into an agreement to acquire Baxter India's form-fill-seal (FFS) infusion business for an undisclosed amount.

    • Biosimilar insulin Glargine to make $100 m from FY18: Biocon

      Biocon R&D team is working on the second phase of the development of oral insulin, and Kiran Mazumdar-Shaw, Chairman & MD, Biocon, hopes that it becomes an approved product in the next 2-3 years.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347